Company
The Binding Site
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
25
510(k), De Novo and PMA
Device trials
0
As lead sponsor, any status
Adverse event reports
18
Received Nov 1, 2025 to Nov 20, 2026
Recall records
29
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name The Binding Site, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name The Binding Site.
Latest FDA decisions
The 8 newest of 25 since 2015.
K250159 · Decided Oct 17, 2025 · 269 days after receipt
Device type: Mass Spectrometric, Immunoglobulins (G, A, M, D, E) (SGG) · Laboratory Medicine & Pathology
K250549 · Decided May 23, 2025 · 87 days after receipt
Device type: Kappa, Antigen, Antiserum, Control (DFH) · Laboratory Medicine & Pathology
K231290 · Decided Jan 24, 2024 · 265 days after receipt
Device type: Kappa, Antigen, Antiserum, Control (DFH) · Laboratory Medicine & Pathology
22 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
No device trials list this company as lead sponsor.
Reports received
18
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
8
44% of reports
Injury reports
10
56% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 1 | 1 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 1 | 1 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 1 | 1 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 1 | 0 | 0 | 0 |
| Jan 25 | 0 | 1 | 0 | 0 |
| Feb 25 | 1 | 1 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 1 | 1 | 0 | 0 |
| Nov 25 | 1 | 1 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 1 | 3 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 1 | 1 | 0 | 0 |
| Jul 26 | 2 | 3 | 0 | 0 |
| Aug 26 | 1 | 0 | 0 | 0 |
| Sep 26 | 0 | 2 | 0 | 0 |
| Oct 26 | 2 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2362-2026 · Started Apr 16, 2026 · Posted by FDA Jun 9, 2026
Reason given: It was reported that plates 2 and 3 were marked as passed , although it appeared that QC had not been performed on these plates, despite samples being measured. The potential clinical hazards include false or missed detection of M-protein (false positive); and falsely elevated or decreased M-protein concentration.
Cause as FDA categorized it: Under Investigation by firm · Device type: Mass Spectrometer For Clinical Multiplex Test Systems (OTA)
Z-0274-2022 · Started Oct 15, 2021
Reason given: Due to calibration curves producing a higher activity than routinely expected and that there may be a decrease in separation between calibrator point 5 and calibrator point 6, which can be exacerbated with calibrator 6 activity reaches the optical ceiling of the SPA+ analyzer.
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Lambda, Antigen, Antiserum, Control (DEH)
Z-2030-2021 · Started May 20, 2021
Reason given: The high and low level "Quality Controls" demonstrate a positive bias of approximately 10% compared to assigned values.
Cause as FDA categorized it: Under Investigation by firm · Device type: Kappa, Antigen, Antiserum, Control (DFH)
26 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.